Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM4 | P08173 | 1/20 | 0.49 |
| ▸ | RAB9A | P51151 | 2/20 | 0.49 |
| ▸ | LMNA | P02545 | 2/20 | 0.49 |
| ▸ | GAA | P10253 | 1/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.49 |
| ▸ | NPC1 | O15118 | 2/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | TP53 | P04637 | 1/20 | 0.48 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.46 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.46 |
| ▸ | F10 | P00742 | 3/20 | 0.46 |
| ▸ | MAPT | P10636 | 2/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17866416 | 0.97 | CHRM4 (0.47) | CHRM4RAB9ALMNAGAASMN1; SMN2 | |
| SCHEMBL1553361 | 0.86 | RAB9A (0.51) | RAB9ALMNANPC1ALDH1A1MEN1 | |
| SCHEMBL6684170 | 0.80 | EGFR (0.65) | RAB9ALMNAGAASMN1; SMN2NPC1 | |
| SCHEMBL5128458 | 0.80 | F10 (0.49) | RAB9ALMNAGAASMN1; SMN2NPC1 | |
| SCHEMBL3432700 | 0.79 | DRD2 (0.45) | LMNAALDH1A1F10 | |
| SCHEMBL10734821 | 0.79 | GRIN2B (0.64) | CHRM4SMN1; SMN2MEN1KMT2AGRIN1 | |
| SCHEMBL22664708 | 0.78 | NPC1 (0.56) | CHRM4RAB9AGAASMN1; SMN2NPC1 | |
| SCHEMBL22664709 | 0.78 | EGFR (0.58) | RAB9AGAASMN1; SMN2NPC1ALDH1A1 | |
| SCHEMBL6899603 | 0.76 | CHRM4 (0.51) | CHRM4GRIN1GRIN2B | |
| SCHEMBL22664705 | 0.76 | EGFR (0.58) | LMNAGAASMN1; SMN2ALDH1A1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 45 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3039126-B1 | SMALL MOLECULE CELLULAR REPROGRAMMING TO GENERATE NEURONAL CELLS | THE J DAVID GLADSTONE INST A TESTAMENTARY TRUST ESTABLISHED UNDER THE WILL OF J DAVID GLADSTONE (US) | 2019-10-09 | — | — | EP | disclosed |
| US-9982231-B2 | Methods for reprogramming differentiated non-cardiac cells into cardiomyocytes | THE J. DAVID GLADSTONE INSTITUTES, A TESTAMENTARY TRUST ESTABLISHED UNDER THE WILL OF J. DAVID GLADSTONE (US) | 2018-05-29 | — | — | US | disclosed |
| US-20160250260-A1 | SMALL MOLECULE CELLULAR REPROGRAMMING TO GENERATE NEURONAL CELLS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2016-09-01 | — | — | US | disclosed |
| US-20160186141-A1 | SMALL MOLECULE CELLULAR REPROGRAMMING TO GENERATE CARDIOMYOCYTES | The J. David Gladstone Institutes, a testamentary trust established under the Will of J. David Glad | 2016-06-30 | — | — | US | disclosed |
| EP-1459743-B9 | Agent for prophylaxis and treatment of glaucoma | SENJU PHARMA CO (JP) | 2012-08-01 | — | — | EP | disclosed |
| EP-1459742-B9 | Agent for prophylaxis and treatment of asthenopia and pseudomyopia | SENJU PHARMA CO (JP) | 2012-05-02 | — | — | EP | disclosed |
| EP-1459743-B1 | Agent for prophylaxis and treatment of glaucoma | SENJU PHARMA CO (JP) | 2011-10-19 | — | — | EP | disclosed |
| EP-1459742-B1 | Agent for prophylaxis and treatment of asthenopia and pseudomyopia | SENJU PHARMA CO (JP) | 2011-10-12 | — | — | EP | disclosed |
| EP-1295607-B9 | ANTITUMOR EFFECT POTENTIATORS | MITSUBISHI TANABE PHARMA CORP (JP) | 2011-10-05 | — | — | EP | disclosed |
| EP-1177796-B1 | Medicament for prevention or therapeutic treatment of liver disease | MITSUBISHI TANABE PHARMA CORP (JP) | 2011-04-27 | — | — | EP | disclosed |
| US-20030096843-A1 | Preventives/remedies for kidney diseases | MITSUBISHI PHARMA CORPORATION (JP) | 2003-05-22 | — | — | US | disclosed |
| EP-1295607-A1 | ANTITUMOR EFFECT POTENTIATORS | Mitsubishi Pharma Corporation (JP) | 2003-03-26 | — | — | EP | disclosed |
| US-6451825-B1 | FOR THERAPY OF HYPERTENSION, A THERAPEUTIC AGENT OF ANGINA PECTORIS, A SUPPRESSIVE AGENT OF CEREBROVASCULAR CONTRACTION, ASTHMA, PERIPHERAL CIRCULATION DISORDER, AS PROPHYLACTIC AGENT OF IMMATURE BIRTH, A THERAPEUTIC AGENT OF ARTERIOSCLEROSIS | MITSUBISHI PHARMA CORPORATION (JP) | 2002-09-17 | — | — | US | disclosed |
| US-20020032148-A1 | Pharmaceutical agent containing Rho kinase inhibitor | MITSUBISHI PHARMA CORPORATION (JP) | 2002-03-14 | — | — | US | disclosed |
| EP-1177796-A1 | PREVENTIVES/REMEDIES FOR LIVER DISEASES | Mitsubishi Pharma Corporation (JP) | 2002-02-06 | — | — | EP | disclosed |
| EP-1174150-A1 | PREVENTIVES/REMEDIES FOR ANGIOSTENOSIS | Mitsubishi Pharma Corporation (JP) | 2002-01-23 | — | — | EP | disclosed |
| EP-1163910-A1 | PREVENTIVES/REMEDIES FOR INTERSTITIAL PNEUMONIA AND PULMONARY FIBROSIS | Welfide Corporation (JP) | 2001-12-19 | — | — | EP | disclosed |
| US-6218410-B1 | ADMINISTERING A PHARMACEUTICALLY EFFECTIVE AMOUNT OF A RHO KINASE INHIBITOR COMPRISING AMIDE COMPOUND FOR INHIBITING RHO KINASE | YOSHITOMI PHARMACEUTICAL INDUSTRIES, LTD. (JP) | 2001-04-17 | — | — | US | disclosed |
| EP-1034793-A1 | PREVENTIVES/REMEDIES FOR GLAUCOMA | Senju Pharmaceutical Co., Ltd. (JP) | 2000-09-13 | — | — | EP | disclosed |
| EP-0956865-A1 | MEDICINES COMPRISING Rho KINASE INHIBITOR | YOSHITOMI PHARMACEUTICAL INDUSTRIES, LTD. (JP) | 1999-11-17 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030096843-A1 | Preventives/remedies for kidney diseases | RHOA, ROCK1, MMP1 | CHRM4 2226/4885RAB9A 375/4885LMNA 1075/4885 |
| US-20160186141-A1 | SMALL MOLECULE CELLULAR REPROGRAMMING TO GENERATE CARDIOMYOCYTES | MYLK2, TNNI3, TNNT2 | CHRM4 3121/4885RAB9A 1294/4885LMNA 591/4885 |
| US-20020032148-A1 | Pharmaceutical agent containing Rho kinase inhibitor | ROCK1, RHOA, ARHGDIA | CHRM4 838/4885RAB9A 404/4885LMNA 2170/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.